WHO ICTRP trial
Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic…
EUCTR2012-004259-36-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2012-004259-36-ES |
|---|---|
| Public title | Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic Phase after prior imatinib treatment. |
| Scientific title | Multicenter, open-label, non-randomized Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) who meet criteria for late suboptimal response after prior imatinib treatment. - DASAPOST |
| Primary sponsor | Fundación PETHEMA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Spain |
| Conditions | Chronic Myeloid Leukemia in Chronic Phase MedDRA version: 14.1 Level: LLT Classification code 10054352 Term: Chronic phase chronic myeloid leukemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: SPRYCEL 20 mg comprimidos recubiertos Pharmaceutical Form: Coated tablet INN or Proposed INN: Dasatinib Monohydrate Other descriptive name: Dasatinib Monohydrate Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Dec 11, 2012 |
| Secondary IDs | DASAPOST |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: